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Abstract
Background: HCV is a positive sense RNA virus affecting approximately 180 million people world wide and about
10 million Pakistani populations. HCV genotype 3a is the major cause of infection in Pakistani population. One of
the major problems of HCV infection especially in the developing countries that limits the limits the antiviral
therapy is the long term treatment, high dosage and side effects. Studies of antigenic epitopes of viral sequences
of a specific origin can provide an effective way to overcome the mutation rate and to determine the promiscuous
binders to be used for epitope based subunit vaccine design. An in silico approach was applied for the analysis of
entire HCV proteome of Pakistani origin, aimed to identify the viral epitopes and their conservancy in HCV
genotypes 1, 2 and 3 of diverse origin.
Results: Immunoinformatic tools were applied for the predictive analysis of HCV 3a antigenic epitopes of Pakistani
origin. All the predicted epitopes were then subjected for their conservancy analysis in HCV genotypes 1, 2 and 3
of diverse origin (worldwide). Using freely available web servers, 150 MHC II epitopes were predicted as
promiscuous binders against 51 subjected alleles. E2 protein represented the 20% of all the predicted MHC II
epitopes. 75.33% of the predicted MHC II epitopes were (77-100%) conserve in genotype 3; 47.33% and 40.66% in
genotype 1 and 2 respectively. 69 MHC I epitopes were predicted as promiscuous binders against 47 subjected
alleles. NS4b represented 26% of all the MHC I predicted epitopes. Significantly higher epitope conservancy was
represented by genotype 3 i.e. 78.26% and 21.05% for genotype 1 and 2.
Conclusions: The study revealed comprehensive catalogue of potential HCV derived CTL epitopes from viral
proteome of Pakistan origin. A considerable number of predicted epitopes were found to be conserved in different
HCV genotype. However, the number of conserved epitopes in HCV genotype 3 was significantly higher in contrast
to its conservancy in HCV genotype 1 and 2. Despite of the lower conservancy in genotype 1 and 2, all the
predicted epitopes have important implications in diagnostics as well as CTL-based rational vaccine design,
effective for most population of the world and especially the Pakistani Population.
Background
Family Flaviviridae comprises small enveloped pathogens
classified in three genera: Flavivirus, Pestivirus,a n dHepa-
civirus. Members of these genera cause various diseases in
humans and other animals such as birds, horses and pigs.
The only genera Flavivirus contain more than 70 members
including Hepatitis C Virus (HCV), Dengue virus, West
Nile virus and tick-borne encephalitis virus [1-3].
HCV is a positive sense RNA virus affecting approxi-
mately 180 million people world wide and rate of infec-
tion in Pakistani population is about 10 million [4,5].
HCV genome contributes about 9400 nucleotides that
encode single polyprotein of approximately 3010 to
3033 amino acids in length [6]. This single polyprotein
is processed by viral as well as host proteases into three
structural proteins (i.e. core, E1 and E2) and four non-
structural proteins (i.e. NS2, NS3, NS4, and NS5A) [7].
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syringes and needles, unsterilized medical equipment, use
of tooth brushes of HCV patients, etc [7] and causes of
acute and chronic infections [8]. Clinical demonstrations
of acute Hepatitus C Viral infection include Jaundice,
Fever, Myalgia, Fatigue, Lethargy, Increased ALT, Anor-
exia and Fulminant hepatic failure [7]. About 80% of
HCV infected individuals develop chronic infections [9].
Chronic liver infections develop chronic hepatitis, cirrho-
sis and hepatocellular carcinoma within a period of 10,
20 and 30 years respectively followed by viral infection
[10,11]. Out of 70-80% chronically infected individuals,
20% develop cirrhosis and 1-5% individuals suffer from
final stage of liver diseases [12]. Hepatic steatosis is the
accumulation of lipids in hepatocytes and is reported for
the cause of cirrhosis [13] with the more severe cases
being reported in patients infected with HCV genotype
3a [14]. The prevelance of steatosis in Pakistani popula-
tion is about 61.5-65.5% compared with 32.8-81.2% in
western countries [15]. The percentage of males infected
with HCV chronic liver stage is higher then females with
the age of patients between 40-50 years [5].
HCV is classified into six genotypes each heaving var-
ious subtypes [16-18]. These genotypes are distributed
differently in various parts of the world with the genetic
variance between them is about one third. The geno-
types 1, 2 and 3 have world wide distribution. But the
significant differences are observed in subtype distribu-
tion. Subtype 1a is mostly found in North America and
Europe followed by 2b and 3a. Subtype 1b is frequently
found in South East Europe and Tunisia and 2c in
North Italy. Genotype 4 is mainly restricted to Middle
East and Central Africa and genotype 5 in South Africa.
Genotype 6 is distributed throughout South East Asia
and also being isolated from Hong Kong and Vietnam
[17]. The most frequent HCV genotypic distribution in
Pakistan is 3a [49.05%] followed by 3b [17.66%] [19].
The knowledge of HCV distribution is crucial for treat-
ment therapy and vaccination because of its predictive
value in terms of response to antiviral therapy and vac-
cination. Effective responses to antiviral therapy are nor-
mally associated with genotype 2 and 3 in comparison
to any other genotype [20].
HCV replicates at about 10
12 new HCV viruses/day.
Replication is carried out by RNA dependent RNA poly-
merase. RNA polymerase lacks the “proofreading” ability
that ensures the high mutation rate of about 8-18 muta-
tions in genomic RNA/year [21,20]. Such a high muta-
tion rate limits the treatment therapy and vaccination.
The current treatment therapy for HCV is INF alpha
along with ribavirin limited to about 50% population
[22]. Although the response rate is not much deterring,
but high dosage, long-term treatment and side effects
limits the usage [23,21]. There is the possibility that
after next few years, new antiviral agents such as inhibi-
tors of the viral protease, helices or polymerase will
further improve the response rate of the current thera-
peutic agents. However, antiviral therapy is not afford-
able in most developing countries, where the prevalence
of HCV is generally the highest. Thus, given the huge
reservoir of HCV worldwide, the development of an
effective vaccine may be the cheapest way to control dis-
ease associated with HCV infection.
Development of an effective HCV vaccine requires
understanding of immune response. Viral immune
response is associated with Major Histocompatabiliy
complex protein (MHC) and T lymphocytes/T cell. MHC
are classified into 2 broad categories, MHC I and MHC II
[24]. MHC initially recognizes the viral antigenic epitopes
and presents to T lymphocytes for degradation. MHC I
presents the antigenic epitopes to CD8+ T cells and
MHC II presents to CD4+ T cells for viral degradation
[25,26]. CD8 T cells also referred to as cytotoxic T cells
(CTL or Tc), limit viral infections by initial recognizing
and their subsequent killing infected cells and secreting
cytokines. CD4 T referred to as helper cells or Th cells
and provides growth factors and signals for generation
and maintenance of CD8 T cells [27]. T cells recognize
t h ea n t i g e n so n l yw h e nt h e ya r ea s s o c i a t e dw i t hM H C ,
surface glycoprotein exposed on surface of all vertebrate
cells. The selection of T cell epitopes is also important
because these are linear and hence easy to synthesize.
A particular vaccine developed against HCV can’tb e
effective for Pakistani population because of variations in
HCV genomic sequences and distribution with regard to
geographical area. Since a large number of Pakistani
population is infected by HCV3a and number of patients
enrolled in public and hospitals is increasing day by day.
So there is a current need to develop a vaccine against
HCV in particular to HCV3a that will cover approxi-
mately maximum Pakistani population. The current vac-
cines are DNA vaccine, Peptide vaccine and epitopic
vaccines. Epitopes are the small antigenic segments of
viral proteins and causes infections in the host. Epitopic
vaccines provide more potent and controlled immune
response and eliminates the potential lethal effects of the
use of whole viral proteins [28]. Promiscuous epitopes
(epitopes capable of binding maximum number of HLA
alleles) may overcome the population coverage. Secondly
the conserved epitopes reduces antigen escape associated
with the viral mutation [29]. So the present study was
designed for the prediction of promiscuous epitopes and
to analyze their conservancy in general population. Any
mutation in the peptide/epitope will lower the conser-
vancy, so it was hypothesized to analyze the pI value of
the mutated amino acid residue, that if remain in the
range as was in original epitope provides the likeliness of
that particular epitope to be used for epitopic vaccine
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immune response with minimum side effects.
Methods
Sequence Retrieval and Analysis
T h es e q u e n c eo ff u l l ys e q u e n c e dH C V3 ag e n o m ea n d
protein of Pakistani origin was retrieved from NCBI
[GU294484]. The number of individual bases in the gen-
ome i.e. the number of adenine; cytosine, guanine and
thymine were calculated from DDBJ database. The mole-
cular weight of proteins, percentage of highly repeated
amino acid and the least repeated amino acid in the viral
protein was calculated by using sequence and search ana-
lysis tool at PIR database (http://pir.georgetown.edu/).
Epitope Prediction
Promiscuous epitopes of HCV 3a viral proteins were
predicted for HLA I and HLA II binding alleles using
freely available immunoinformatics tools such as
ProPred I, and ProPred respectively. In comparison to
other epitope prediction tools, Propred 1 and Propred
cover maximum number of Human Leukocyte antigens
i.e. HLA and being used for epitopic prediction for HBV
and tuberculosis. ProPred1 allows the user to predict
antigenic apitopes for 47 MHC I alleles and ProPred
allows epitopes prediction for 51 MHC II alleles. Predic-
tions through these tools can be carried out at various
thresholds from 1 to 10%. The algorithms designed for
the working of these tools are based on linear coeffi-
cients of matrices. Maximum of the matrics were
retrieved from BIMASS where the score of each peptide
is calculated in multiplication and/or sum up manner.
For example the score of following peptide “PACDP-
GRAA” can be calculated by using following equation:
Score = P(1) × A(2) × C(3) × D(4) × P(5) × G(6) × R
(7) × A(8) × A(9)
Score = P(1) + A(2) + C(3) + D(4) + P(5) + G(6) + R
(7) + A(8) + A(9)
Where P (1) is score of P at position 1.
Only the promiscuous epitopes with score higher than
the chosen threshold score were assigned as predicted
epitopes for the selected HLA alleles [30]. For the fol-
lowing study the default threshold i.e. 4% was used
where the sensitivity and specificity are nearly the same
for most of the HLA alleles available in ProPred1 and
ProPred server. Moreover, MHC I alleles were predicted
by keeping the proteosome and immunoproteosome fil-
ters on at 5% threshold because most of the MHC bin-
ders having a proteosomal cleavage site at C-terminal
have higher likelihood to be T-cell epitopes [31]. The
predicted promiscuous epitopes were positioned in the
table in a decreasing order of their score.
Epitope Conservancy Analysis
All the predicted epitopes of HCV 3a proteins of Pakis-
tani origin were subjected for worldwide conservancy
analysis among HCV genotype 1, 2 and 3. 5 sequences
against each HCV protein (used for epitope prediction)
were retrieved from NCBI randomly. The predicted epi-
topes of HCV 3a (Pakistani origin) along with 5 selected
sequences of individual genotypes (genotype 1, 2 and 3;
one at a time) were submitted to epitope conservancy
analysis tool available at IEDB database (http://tools.
immuneepitope.org/tools/conservancy/iedb_input). All
the epitopes having 77-100% conservancy were selected
while rejecting the epitopes having variation at the
anchor residues. The anchor residues in the predicted
epitopes were highlighted by making it bold. The epi-
topes that were 100% conserved in the selected proteins
of the 3 viral genotypes 1, 2 and 3 were also fully bold.
Epitopes with 88/77% conservancy were with single or
double amino acid variation respectively and to highlight
them bold format was used in the conservancy column
against each genotype.
Asteric sign (*) indicates that one out of five selected
sequences either does not respond to epitope conservancy
or have conservancy lower then 77%. Double asteric sign
(**) indicates that only one sequence responds for
77-100% conservancy to the selected epitope.
Validation of varied amino acids using pI value
The Peptides with single or double amino acid variation
were analyzed for their hydropathic characteristics or pI
value [32]. The pI gives the information that the varied
residue retained the amino acid group or diverted from
its normal group in a particular peptide under consid-
eration and thus provides information to be used or
their rejection. All the varied amino acid residue with
diverted group (with considerable change of pI value)
were separated from other using superscript “D” for sin-
gle variation and “DD” for diverted group for doubly
varied residues. The superscript “D” in doubly varied
residues of particular peptides represents the partial var-
iation i.e. one of the varied residue retained the amino
acid group while other residue shifted the amino acid
group by a considerable change of pI value.
Results
HCV 3a genome of Pakistani origin comprises 9474 bp
with GC content 2622 and 2700 respectively. The GC
contents are 12.35% higher then AT contents. The gen-
ome encodes a polyprotein that subsequently get frag-
mented into structural and non structural protein of
obvious molecular weight. The envelope protein E2 com-
prises highest moleculat weight 38755.3 KDa (Table 1).
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the highest percent of repetition (13.1%) in E2 protein.
The least repeated residue of E2 is a basic polar Lysine
(K) (1.4%). The shortest segment viral protein is NS4a
(5751.69 KDa molecular weight) comprising 54 amino
acid residues. Leucine (L) and Valine (V) have highest
percentage of repetition (14.8) and Histidine (H), Methio-
nine (M), Threonine (T) and Tryptophan (W) are the
least repeated amino acid residues (1.9%). The molecular
weight of other viral proteins and percent repetition of
their amino acid residue for were listed in Table 1. The
percentage of amino acid residues gives an out look for
their pI value and their probability of incidence in the
antigenic epitopes.
F (Phenylalanine), I (Isoleucine), L (Leucine), M
(Methionine), V (Valine), W (Tryptophan) and Y (Tyro-
sine) were mainly the anchor residues for MHC II pre-
dicted epitopes and are nonpolar in nature. Total 150
epitopes were predicted against 51 alleles of MHC II
(Table 2). The highest number of epitopes was represented
by E2 protein comprising 20% of all MHC II predicted
epitopes. VFLLNPCGL, FVILVFLLL, WHINSTVLH,
FNLLDVPKA, LELINTHGS, VQYLYGVGS are the pro-
miscuous binders of 45-50 MHC II alleles. E2 is followed
by NS2 and NS4B proteins representing 14.66% of the pre-
dicted MHC II epitopes. In case of NS2 VRAHVLVRL,
VILLTSLLY and VRLCMFVRS are the best binders both
in term of score and the HLA allele coverage (50-51 MHC
II alleles). FFNILGGWV, VNLLPAILS and VVNLLPAIL
are the best binders of NS4b protein both in terms of
HLA coverage (41 HLA coverage for the first epitope and
51 for the next 2 epitopes) and binding efficiency.
LVVGVICAA, FNILGGWVA, WQKLEAFWH, IQY-
LAGLST and VVGVICAAL are also the epitopes of good
quality covering 31 to 35 HLA alleles available in ProPred.
For the NS5a_1a only three epitopes (MRLAGPRTC,
FISCQKGYK and VVSTRCPCG) were predicted as pro-
miscuous binders with the binding score higher then
the selected threshold. Out of these three epitopes
MRLAGPRTC is capable of binding all the HLA alleles
available in ProPred server while FISCQKGYK and
VVSTRCPCG bind 22 and 25 HLA alleles respectively.
The predicted promiscuous binders against other proteins
were also summarized in table 2.
Total 69 epitopes were predicted as promiscuous epi-
topes for MHC I alleles. The anchor residues in case of
MHCI are quite varying both in amino acid residues
and also in their nature. Mostly represented anchor resi-
dues are neutral nonpolar and neutral polar. However,
quite small percentage of anchor residues were also
acidic polar and basic polar in nature. The highest num-
ber of MHC I binding epitopes were represented by
NS4b protein comprising 26% of all MHC I predicted
epitopes. NFVSGIQYL epitope of NS4b is the best pro-
miscuous binder of highest binding score. NS4b is fol-
lowed by NS2, E2 and NS3 proteins representing 20.28%
(NS2 epitopes) and 11.59% (for E2 and NS3). In case of
NS2, 14 promiscuous epitopes were predicted with vary-
ing binding efficiency. GSRDGVILL, DGVILLTSL,
WAAAGLKDL and LQVWVPPLL are the good binders
both in term of score and the HLA allele coverage (21,
28, 27 and 28 alleles respectively). E2 predicted epitopes
covers 20 to 28 HLA alleles except the PLLHSTTEL
epitope that covers only 11 HLA alleles but with highest
binding efficiency. NS3 epitopes covers 8 to 25 HLA
alleles and were also ranked on the basis of their bind-
ing efficiency predicted by the score. The least repre-
sented epitopes were by NS5a_1a. It comprises only one
epitope (HVKNGSMRL) as predicted promiscuous bin-
ders for 16 MHC I binding alleles. The promiscuous
binders of MHC I for other proteins were also predicted
and summarized in table 3.
Out of total 150 predicted MHC II epitopes, 75.33%
were (77-100%) conserve in genotype 3 (Table 1) against
the randomly selected viral proteins. Out of 75.33% con-
served peptides of genotype 3, 71.68% peptides were
100% conserve while 22.12% peptides were having single
residue variation (88% epitope conservancy). Only the
Table 1 It comprises the data of HCV genome size, Proteins, Molecular weight and %age of highly repeated and least
repeated amino acid residues in individual bases
Bases No. Proteins aa Number Mol. Wt. Highly repeated aa % of repetition Least repeated aa % of repetition
Total bp 9474 Capsid 114 12985.8 R 18.4 C/F 0.9
A 1974 Core 75 7638.88 L 16 E/K/M/Y 1.3
C 2700 E1 190 20643.9 V 11.1 E 1.1
G 2622 E2 350 38755.3 L 13.1 K 1.4
T 2178 NS3 149 15423.6 A/G 11.4 N 0.7
NS4a 54 5751.69 L/V 14.8 H/M/T/W 1.9
NS4b 194 20167.5 A 13.4 C 0.4
NS5a-1a 62 6700.72 G 14.5 E/D 1.6
NS5a-1b 101 11224.6 P 11.9 K/W 1
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Epitope start Position Predicted T-cell epitopes HLA alleles HCV genotype 1 HCV Genotype 2 HCV Genotype 3
Capsid
43 LGVRATRKA 23 LGVRATRKT
D LGVRATRKT LGVRATRKT
D
36 LPRRGPRLG1 5 LPRRGPRLG LPRRGPRLG LPRRGPRLG
106 WGPNDPRRR 16 WGPTDPRRR WGPTDPRHR
D WGPNDPRRR
34 YVLPRRGPR 24 YLLPRRGPR YLLPRRGPR YVLPRRGPR
21 VKFPGGGQI 8 VKFPGGGQI * VKFPGGGQI VKFPGGGQI
35 VLPRRGPRL 9 VLPRRGPRL
45 VRATRKASE 25 VRATRKTSE
D VRATRKTSE
D VRATRKTSE
D
30 VGGVYVLPR 39 VGGVYLLPR * VGGVYLLPR VGGVYVLPR
15 IRRPQDVKF 6 IRRPQDVKF
95 WLLSPRGSR 28 WLLSPRGSR WLLSPRGSR WLLSPRGSR
29 IVGGVYVLP 3 IVGGVYLLP * IVGGVYLLP IVGGVYVLP
82 WPLYGNEGC 10 WPLYGNEGC WPLYGNEGC WPLYGNEGC
85 YGNEGCGWA 11 YGNEGCGWA YGNEGCGWA * YGNEGCGWA
33 VYVLPRRGP 1 VYLLPRRGP VYLLPRRGP VYVLPRRGP
Core
61 FLLALLSCL 50 FLLALLSCL FLLALLSCI FLLALLSCL
64 LALLSCLIH 45 LALLSCLTV
DD LALLSCLIH *
15 FADLMGYIP 41 FADLMGYIP FADLMGYIP FADLMGYIP
24 LVGAPVGGV 44 LVGAPLGGA LVGAPVGGV *
63 LLALLSCLI 36 LLALLSCLT
D LLALLSCIT
D LLALLSCLI *
62 FLLALLSCL 24 FLLALLSCL FLLALLSCI FLLALLSCL *
32 VARALAHGV 10 VARALAHGV VARALAHGV
21 YIPLVGAPV 28 YIPLVGAPL YIPVVGAPL YIPLVGAPV
19 MGYIPLVGA 26 MGYIPLVGA MGYIPVVGA MGYIPLVGA
E1
58 YVGATTASI 41 YVGATTASI *
140 MVVAHILRL 39 MVVAHILRL*
2 WRNTSGLYV 27 WRNTSGLYV
138 VGMVVAHIL 28
56 VKYVGATTA 21 VRYVGATTA
D *
9 YVLTNARSN 31 YVLTNDCSN
DD
161 WGVLAGLAY 15 WGVLAGMAY WGVVFGLAY WGILAGLAY
93 FLVGQAFTF 11 FLVGQLFTF FLVGQAFTF
181 IIMVMFSGV 91 IIMVMFSGV
130 MMMNWSPAV 35 MMMNWSPTA
D MMMNWSPAM
134 WSPAVGMVV 6 WSPAMGMVV *
132 MNWSPAVGM 14 MNWSPAMGM *
169 YYTMQGNWA 18 YYSMQGNWA
47 WTPMTPTVA 21 WTPVTPTVA *
172 MQGNWAKVA 25 MVGNWAKVL
D MQGAWAKVI
D WTPVTPTVA
D *
145 ILRLPQTLF 19 ILRLPQTLF
E2
122 MLPHHRPVV 3
151 VFLLNPCGL 48
337 WEFVILVFL 4 WEFIVLVFL
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339 FVILVFLLL 46 FIVLVFLLL
35 WHINSTVLH 41
342 LVFLLLADA LLFLLLADA LLFLLLADA LVFLLLADA
100 VLLAYAPRP 50
198 FRPLLPHRL 47
218 VRLGALVDT 12
62 FNLLDVPKA 45
26 LELINTHGS 46
57 FYYHKFNLL 12 FYYHKFNSS
D FYYHKFNST
DD
83 VGPLDRCQH 26
58 YYHKFNLLD 24
286 LLHSTTELA 17 LLHSTTEWA LLHSTTELA
129 VVVGTTDPK 14 VVVGTTDKL
DD VVVGTTDRL
DD * VVVGTTDAK
320 VQYLYGVGS 46 VQYLYGVGS VQYLYGVGS
159 LLVVGGLGG 14
293 LAILPCSFT 7 LAILPCSFT
335 LKWEFVILV 4 LKWEFIVLV
322 YLYGVGSGM 5 YLYGVGSSI
D YLYGVGSGM
300 FTPMPALST 17 FTPMPALST
245 FYTVQGEDV 4
18 IVRGPEQRL 26
100 VLLAYAPRP 4
257 VWHRFTAAC 19 VEHRLTAAC
D *
206 LLQETSRGH 8
1 YITGGTAAR 8
267 WTRGERCDI 10 WTRGERCEI
310 IHLHQNIVD 11 IHLHQNIVD * IHLHQNIVD
NS2
101 VRAHVLVRL 51 VRAHVLVRL
62 VILLTSLLY 50 VILLTSLLY *
73 LVFDIAKLL 24 LVFDITKLL
D * LVFDITKLL
D *L IFDITKLL
D
153 LKDLAVATE 7 LKDLAVATE *
113 FVRSVTGGK 37
130 VGRWFNTYL 11 VGRWFNTYL *
123 FQMAILSVG 31 FQMIILHVG
D
137 YLYDHLAPM 21 YLYDHLAPM
74 VFDIAKLLIA 23 VFDITKLLLA
D * VFDITKLLLA
D
107 LVRLCMFVR 36 LVRLCMLVR
108 VRLCMFVRS 51 VRLCMLVRS *
89 YFVRAHVLV 33 YFVRAHVLV
11 ILVLFGFFT 15
37 YAICRCESA 18 IINGLPVSA
D YTICRCESA
D *
33 WWNQYAICR 8 WWNQYTICR
D
185 ILCGLPVSA 10 IINGLPVSA * IINGLPVSA ILCGLPVSA
145 MQHWAAAGL 18 MQHWAAAGL
50 VPPLLARGS 21 VPSLLARGS
D *
88 LYLIQAAIT 35 LYLIQTAIT
D *
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158 VATEPVIFS 14 VAVEPVVFS
D VAVEPVVFS VATEPVIFS
37 YAICRCESA 19 YTICRCESA
D *
175 WGADTAACG 11 WGADTAACG * WGADTAACG * WGADTAACG
NS3
4 VQVLSTATQ 46 VQIVSTATQ VQVLSSVTQ
D
43 LQMYTNVDQ 42
129 VCTRGVAKA 21 VCTRGVAKA VCARGVAKS
DD *
24 WTVYHGAGS 13 WTVYHGAGT WTVYHGAGN
84 VIPARRRGD 18 VIPVRRRGD *
138 LQFIPVETL 45
140 FIPVETLST 43 FIPVENLGT
D
6 VLSTATQTF 19 IVSTATQTF
53 LVGWPAPPG 29 LVGWPAPQG LVGWPSPPG
D
27 YHGAGSRTL 22 YHGAGTRTI
14 FLGTTLGGV 10
77 LVTREADVI 25 LVTRHADVI
D * LVTRNADVI
D *
98 LSPRPLACL 12 LSPRPLSTL
D
124 IFRAAVCTR 44
NS4a
23 VVIVGHIEL 43 VVIVGRIIL
DD VVIVGRIVL
DD VVIVGHIEL
3 WVLLGGVLAA 43 WVLVGGVLAA WVLVGGVLAA WVLLGGVLAA
4 VLLGGVLAAL 40 VLVGGVLAAL VLVGGVLAAL VLLGGVLAAL
38 VPDKEVLYQ 11 VPDKEVLYQ *
24 VIVGHIELG 8 VIVGHIELG
10 LAALAAYCLS 8 LAALAAYCLT * LAALAAYCLS LAALAAYCLS
16 YCLSVGCVV 6 YCLSTGCVV
D YCLSVGCVV
26 VGHIELGGK 9 VGHIELGGK
25 IVGHIELGG 29 IVGHIELGG
20 VGCVVIVGH 15 VGCVVIVGH
9 VLAALAAYC9 VLAALAAYC* VLAALAAYC VLAALAAYC
29 IELGGKPAL 14 IELGGKPAL
NS4b
81 FFNILGGWV 41 FFNILGGWV
153 VNLLPAILS 51 VNLLPAILS VNLLPAILS VNLLPAILS
152 VVNLLPAIL 51
39 WNFVSGIQY 16 WNFISGIQY WNFISGIQY WNFVSGIQY
165 LVVGVICAA 35 LVVGVVCAA LVVGVVCAA LVVGVICAA
82 FNILGGWVA 32 FNILGGWVA FNILGGWVA FNILGGWVA
81 FFNILGGWV 5 FFNILGGWV
63 LMAFAASVT 9 LMAFTASIT
D LMAFTAAVT
DD LMAFTASVT
D
27 WQKLEAFWH 35 WQKLEVFWA
D WQKLEAFWH *
167 VGVICAALL 11 VGVVCAAIL VGVVCAAIL VGVICAAIL
45 IQYLAGLST 35 IQYLAGLST IQYLAGLST IQYLAGLST
64 MAFAASVTS 23 MAFTASITS MAFTAAVTS
DD MAFTASVTS
D
84 ILGGWVATH 24 ILGGWVAAQ
DD ILGGWVAAQ
DD ILGGWVATH
103 VVSGLAGAA 10 VGAGLAGAA
D VVSGLAGAA
166 VVGVICAAL 31 VVGVVCAAI VVGVVCAAI VGVICAAIL
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85 LGGWVATHL 3 LGGWVAAQL
DD LGGWVAAQL
DD LGGWVATHL
60 VASLMAFAA 15 VASLMAFTA
D
41 FVSGIQYLA 8 FISGIQYLA FISGIQYLA FVSGIQYLA
139 FKIMGGELP 21 FKIMSGEVP
D FKIMGGEFP*
9 LQRATQQQA 14 LQRATQQQA *
122 LDILAGYGA 6 LDILAGYGA *
104 VSGLAGAAI 3 VSGLAGAAI
NS5a_1a
39 MRLAGPRTC 51 MRIVGPRTC * FISCQKGYR
D * MRLAGPRTC*
3 FISCQKGYK 22 FFSCQRGYK
DD * FISCQKGYK *
19 VVSTRCPCG 25 VMSTRCPCG *
NS5a_1b
73 LLRDEITFV 20 LLRDEVTFQ
D* LLRDEVTFQ
D ** LLRDEITFV *
16 WRVAANSYV 33 WRVAAEEYV
DD * WRVAASEYV
D WRVAANSYV
55 FTEVDGVRL 4 FTELDGVRL* FTEVDGVRL ** FTEVDGVRL
80 FVVGLNSYA 25 FVVGLNSYA *
32 FHYITGATE 16 FHYITGATE
61 VRLHRYAPP 27 VRLHRYAPA* VRLHRYAPP *
87 YAIGSQLPC 20 YVVGSQLPC * VRLHRYAPA
D ** YAIGSQLPC *
23 YVEVRRVGD 14 YVEVTRVGD
D * YVEVTRVGD
D ** YVEVRRVGD
Bold amino acid residues in T-cell Epitope column indicates the anchor residues.
Bold individual amino acid residues in HCV Genotype 1, 2 and 3 columns indicated the variation in peptide in comparison to the predicted epitope.
*Indicates that one of the protein sequence selected for epitope conservancy either does not respond or have conservancy lower then 70%.
** Indicates that only one of the protein sequence from selected sequences respond to epitope conservancy.
D Indicates that amino acid residue in case of single/double variation diverted their group compared to primary epitope using pI value.
DD Indicates that both amino acid residues in case of double variation diverted their group compared to primary epitope using pI value.
Table 3 Predicted HLA I epitopes HCV Proteins of Pakistani origin and their conservancy in Genotype 1, 2 and 3
worldwide
Epitope start Position Predicted T-cell epitopes HLA alleles HCV genotype 1 HCV Genotype 2 HCV Genotype 3
Capsid
38 RRGPRLGVR 9 RRGPRLGVR RRGPRLGVR RRGPRLGVR
35 VLPRRGPRL 25 VLPRRGPRL
Core
55 PGCSFSIFL 8 PGCSFSIFL PGCSFSIFL PGCSFSIFL *
41 RALEDGINF 20 RVLEDGVNF ** RALEDGINF *
7 VIDTLTCGF 15 VIDTLTCGF VIDTITCGF * VIDTLTCGF *
35 ALAHGVRAL 24 ALAHGVRVL ALAHGVRVL ALAHGVRAL *
24 LVGAPVGGV 18 LVGAPLGGA * LVGAPVGGV *
26 GAPVGGVAR 9 GAPLGGAAR * GAPLGGVAR GAPVGGVAR *
E1
135 SPAVGMVVA 14 SPAMGMVVA *
86 GDVCGAVFL 19 GDLCGSVFL
D GDVCGAVMI GDMCGAVFL *
144 HILRLPQTL 22 HILRLPQTL *
156 IAGAHWGVL 27 IAGAHWGVL IAGAHWGIL
64 ASIRGHVDL 25 ASIRSHVDL
D
E2
285 PLLHSTTEL 11 PLLHSTTEW
D PLLHSTTEL
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Page 8 of 13Table 3 Predicted HLA I epitopes HCV Proteins of Pakistani origin and their conservancy in Genotype 1, 2 and 3
worldwide (Continued)
305 ALSTGLIHL 25 ALTTGLIHL ALSTGLIHL
227 CSFTPMPAL 20 CSFTTLPAL
D * CSFTPMPAL
71 QQLQAHHFL 27
157 CGLLVVGGL 28
212 RGHIQPVRL 24
6 TAARGGQGL 25
157 CGLLVVGGL 28
NS2
172 VITWGADTA 6 VITWGADTA *
75 FDIAKLLIA 12 FDITKLLLA
D FDITKLLLA
D * FDITKLLIA
D
70 YPSLVFDIA 15 YPSLIFDIT
DD
57 GSRDGVILL 21 GGRDAVILL
D ** GGRDAVILL
D * GSRDGVILL
60 DGVILLTSL 26 DGVILLTSL *
148 WAAAGLKDL 27 WAASGLRDL
DD** WAAAGLKDL *
50 VPPLLARGS 11 VPPLLARGS *
46 LQVWVPPLL 28 LHVWVPPLN
DD LHVWVPPLN
DD * LQVWVPPLL *
117 VTGGKYFQM 16 VVGGKYFQM
D *
65 LTSLLYPSL 23 LTSLLYPSL
6 TLGAGILVL 48 TLGAGVLVL *
73 LVFDIAKLL 31 LVFDITKLL
D LVFDITKLL
D *L IFDITKLL
D
145 MQHWAAAGL 26 MQHWAAAGL
178 DTAACGDIL 21 DTAACGDII DTAACGDII
D * DTAACGDIL
NS3
119 GHVAGIFRA 8 GHAVGIFRA * GHVVGLFRA *
27 YHGAGSRTL 14 YHGAGTRTI YHGAGNKTL
D
128 AVCTRGVAK 8 AVCTRGVAK AVCTRGVAK *
57 PAPPGAKSL 11 PAPQGARSL
DD *P SPPGTKSL
DD
98 LSPRPLACL 25 LSPRPLSTL
D
95 ASLLSPRPL 24
130 CTRGVAKAL 20 CTRGVAKAV
7 LSTATQTFL 24
NS4a
3 WVLLGGVLA 11 WVLVGGVLA WVLVGGVLA WVLLGGVLA
23 VVIVGHIEL 21 VVIVGRIIL
DD VVIVGRIVL
DD VVIVGHIEL
10 LAALAAYCL 24 LAALAAYCL * LAALAAYCL LAALAAYCL
5 LLGGVLAAL 27 LVGGVLAAL LVGGVLAAL LLGGVLAAL
NS4b
96 PQSSSAFVV 6 PQSSSAFVV
40 NFVSGIQYL 30 NFISGIQYL NFISGIQYL NFVSGIQYL
81 FFNILGGWV 13 FFNILGGWV
46 QYLAGLSTL 17 QYLAGLSTL QYLAGLSTL QYLAGLSTL
102 FVVSGLAGA 9 FVGAGLAGA
D FVVSGLAGA
54 LPGNPAVAS 14 LPGNPAIAS LPGNPAIAS LPGNPAVAS
161 SPGALVVGV 14 SPGALVVGV SPGALVVGV SPGALVVGV
141 IMGGELPNA 7 IMGGEFPTA
D *
164 ALVVGVICA 11 ALVVGVVCA ALVVGVVCA ALVVGVICA
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Page 9 of 1340% peptides of singly varied residues diverted their
amino acid group and the pI value while 60% singly var-
ied residues retained the amino acid group as was in the
predicted epitope of HCV 3a proteins. 6.19% peptides
comprised the 77% epitope conservancy because of dou-
ble residue variation in the peptides of general popula-
tion in contrast to predicted epitopes of HCV 3a of
Pakistani origin. Out of 6.19%, doubly varied amino acid
residues 42.85% peptides retained their amino acid
group and nearly same pI value as in case of predicted
epitope while 28.57% peptides were having partial group
divertion and 28.57% (of doubly varied amino acid resi-
dues) peptides diverted their amino acid group because
of considerable variation in the pI value. Similar data
was also obtained for the HCV genotype 1 and 2 con-
sisting 47.33% and 40.66% conservancy respectively.
However, in contrast to genotype 3, only 23.94% pre-
dicted epitopes were 100% conserve in randomly
selected sequences of genotype 1 and 22.95% in geno-
type 2. Their rate of single/double residue variation was
also predicted and expressed as figure 1.
Out of total 69 predicted MHC I epitopes, 78.26%
were (77-100%) conserve in genotype 3 (Table 2) against
the randomly selected viral proteins. Out of 78.26% con-
served peptides of genotype 3, 72.22% peptides were
100% conserve while 22.22% peptides were having single
residue variation (88% epitope conservancy). 40.66%
peptides of singly varied residues retained the amino
acid group as was in the predicted epitope of HCV 3a
proteins while 58.33% singly varied residues diverted
their amino acid group and the pI value. 5.5% peptides
comprised the 77% epitope conservancy because of dou-
ble residue variation in the peptides of general popula-
tion in contrast to predicted epitopes of HCV 3a of
Pakistani origin. Out of 5.5%, doubly varied amino acid
residues 66.66% peptides were having partial group
divertion and 33.33% (of doubly varied amino acid resi-
dues) peptides diverted their amino acid group because
of considerable variation in the pI value. Similar data
was also obtained for the HCV genotype 1 and 2 con-
sisting 55.07% conservancy. However, in contrast to gen-
otype 3, only 21.05% predicted epitopes were 100%
conserve in randomly selected sequences of genotype 1
and 2. Their rate of single/double residue variation was
also predicted and expressed as figure 2.
Discussion
The modern technique for control of HCV infection is a
vaccine preparation that can specifically induce anti-
body-mediated immunity. The rapid advancements in
the computational methodologies and immunoinfor-
matics/immuno-bioinformatics provide new strategies
for the synthesis of antigen specific epitopic vaccine
against infectious agents such as viruses and pathogens.
Epitopic vaccine against HIV, malaria and tuberculosis
provided promising results and supported the defensive
Table 3 Predicted HLA I epitopes HCV Proteins of Pakistani origin and their conservancy in Genotype 1, 2 and 3
worldwide (Continued)
117 LGRVLLDIL 22 LGKVLVDIL
D*L G KVLVDIL
D LGKVLLDIL
D *
59 AVASLMAFA 9 AIASLMAFT
D AIASLMAFT
D AVASLMAFT
D
152 VVNLLPAIL 15
113 GIGLGRVLL 24 GIGLGKVLL
D *
56 GNPAVASLM 12 GNPAIASLM GNPAIASLM GNPAVASLM
52 STLPGNPAV 21 STLPGNPAI STLPGNPAV STLPGNPAV
85 LGGWVATHL 26 LGGWVAAQL
DD LGGWVAAQL
DD LGGWVATHL
145 ELPNAEDVV 11
99 SSAFVVSGL 22 SSAFVVSGL
NS5a_1a
33 HVKNGSMRL 16 HVKNGSMRI * HVKNGSMRI ** HVKNGSMRL
NS5a_1b
49 VPAAEFFTE 6 VPAPEFFTE * VPAPEFFTE ** VPAAEFFTE
79 TFVVGLNSY 10 TFQVGLNQY
D *T F TVGLNSF
D *T F TVGLNSY
D *
76 DEITFVVGL 19 DEVTFQVGL
D *D E VTFTVGL
D* DEITFMVGL *
Bold amino acid residues in T-cell Epitope column indicates the anchor residues.
Bold individual amino acid residues in HCV Genotype 1, 2 and 3 columns indicated the variation in peptide in comparison to the predicted epitope.
*Indicates that one of the protein sequence selected for epitope conservancy either does not respond or have conservancy lower then 70%.
** Indicates that only one of the protein sequence from selected sequences respond to epitope conservancy.
D Indicates that amino acid residue in case of single/double variation diverted their group compared to primary epitope using pI value.
DD Indicates that both amino acid residues in case of double variation diverted their group compared to primary epitope using pI value.
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Page 10 of 13Figure 1 A comparative analysis of HCV 3a Predictive epitopes against MHC II alleles and their conservancy analysis in Genotype 1, 2
and 3 worldwide.
Figure 2 A comparative analysis of HCV 3a Predictive epitopes predicted against MHC I and their conservancy analysis in Genotype 1,
2 and 3 worldwide.
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Page 11 of 13and therapeutic uses of these vaccines [33]. Thus in the
present study, a new systematic immunoinformatics
approach was applied for the predicted antigenic epi-
topes of HCV 3a proteins of Pakistani origin followed
by diversity and conservancy in other genotypes (1,2
and 3) in randomly selected HCV sequences from NCBI
and mainly belong to Thailand, Cuba, UK, USA, China,
Japan, France, Italy and Germany. The immunogenic
epitopes identified were nanomers and could be used
diagnostically to detect HCV specific CTL responses in
the patients and after vaccination. A CTL based HCV
vaccine might not efficient enough to prevent from
infection but it might protect the body from the disease.
The analysis showed that the minimal number of epi-
topes required to represent the complete anigenicity of
the whole proteins are significantly smaller then
required to represent full length proteins. The majority
of the epitopes reported here had intermediate to high
HLA binding affinity.
By the use of an efficient CTL based epitope delivery
technology; the predicted epitopes could eventually
become vaccines in their own or fused as polytopes.
The design of the HCV vaccine using conserved epi-
topes can avoid viral mutation and thus provides more
efficient results. The study shows that the predicted epi-
topes were highly conserved in HCV genotype 3 and
also but less conserved in genotype 1 and 2 both for
MHC I and MHC II. Moreover, to ensure the viral
detection at all stages of its intracellular evolution we
have used all the viral proteins. Therefore, the total
number of predicted epitopes were also maximized in
correspond to the number of covered proteins used for
the analysis.
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